Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 8554-8554
Author(s):  
Vijayveer Bonthapally ◽  
Marie-Helene Lafeuille ◽  
Jonathan Fortier ◽  
Mei Sheng Duh ◽  
Yvette Ng ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Retrospective Analysis ◽  
Cell Lymphoma ◽  
Treatment Patterns ◽  
Mantle Cell

scholarly journals 259O Treatment patterns and outcomes in older patients with mantle cell lymphoma in an Asian population

2020 ◽  
Vol 31 ◽  
pp. S1344
Author(s):  
X. Yang ◽  
L.P. Khoo ◽  
E.W.Y. Chang ◽  
V.S. Yang ◽  
E.Y.L. Poon ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Older Patients ◽  
Cell Lymphoma ◽  
Asian Population ◽  
Treatment Patterns ◽  
Mantle Cell

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4942-4942
Author(s):  
Ana García-Noblejas ◽  
Belén Navarro Matilla ◽  
Carolina Da Silva Rodriguez ◽  
Raquel De Oña Navarrete ◽  
María José Ramirez Sánchez ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Mantle Cell Lymphoma ◽  
Retrospective Analysis ◽  
Conflicts Of Interest ◽  
Cell Lymphoma ◽  
Alkylating Agents ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Median Number ◽  
Mantle Cell

Abstract Abstract 4942 INTRODUCTION. Patients with Mantle cell lymphoma (MCL) have an adverse outcome after relapse due to chemorefractory disease with conventional treatments. Bendamustine, a nitrogen mustard compound chemically related to the alkylating agents, has demonstrated high efficacy with a low toxicity profile in reported clinical trials. AIM. To analyze the Spanish experience in patients with relapsed/refractory MCL treated with Bendamustine. METHODS. Retrospective analysis of spanish experience in relapsed/refractory MCL treated with Bendamustine alone or in combination. This study has been approved by local ethical committees. RESULTS. Currently, there are 36 patients registered and 28 are available for this analysis. Patients'characteristics: 69% male, median age 65 years old (range 41–81), 87% ECOG≤ 1, 83% Ann Arbor stage IV, 37% high risk MIPI and 9% blastic variant. Previous regimens were CHOP or CHOP like ± R in 42.5%, HyperCVAD/MtxAraC ± R in 42.5%, R-CVP in 9% and other regimens in 6%. Median number of previous treatments were 2.6 (range 1–6), all patients had received prior Rituximab and 73% had chemosensitive disease to the last treatment. Bendamustine regimen was R-B (R-375mg/m2 D1, B-90 mg/m2 D1-2) in 78% patients, R-B with B-70 mg/m2 in 8%, B alone in 3%, R-B-Bortezomib in 3% and R-B plus consolidation (SCT, Y90Ibritumomab-tiuxetan) in 8%. Median number of cycles was 4.61 (range 1–7). G- CSF support was administered in 43% of cycles. Response: Overall response rate was 73%, with 43% CR & uCR and 30% PR. Survival: Median overall survival from diagnosis is 8,26 years (range: 1.6–11,6 years) without plateau. Median progression free survival (PFS) after Bendamustine treatment was 16 months (95% CI: 11.7–20.4), data that compares favourably with patients' PFS to previous therapy (12 months, 95% CI: 6.5–17.5). Median PFS for patients who achieved CR/uCR is 32.6 months (95% CI: 19.9–45.4) versus 11 months in patients with PR (95% CI: 3.9–18.8). With a median follow-up for surviving patients of 12 months since Bendamustine treatment, the estimated OS at 3 years is 47% (+ SD 14%). Toxicity: No treatment related mortality has been described so far. Over 152 cycles, only 10 hospitalizations due to febrile neutropenia were reported. No one case of lysis tumoral syndrome has been reported. CONCLUSION. Bendamustine plus Rituximab is a good rescue treatment in non selected pretreated patients with mantle cell lymphoma. CR rate and duration of response seem to reproduce in current clinical practice the good data reported in previous clinical trials and compares favourably with other available treatments. Disclosures: No relevant conflicts of interest to declare.

Matched Unrelated Donor Stem Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma. A Retrospective Analysis from the EBMT Lymphoma Working Party.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3123-3123 ◽  
Author(s):  
Irit Avivi ◽  
Carme Canals ◽  
Goli Taghipour ◽  
Jurgen Finke ◽  
Liisa Volin ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Retrospective Analysis ◽  
Cell Lymphoma ◽  
High Dose ◽  
Unrelated Donor ◽  
Refractory Disease ◽  
Long Term Outcome ◽  
Mantle Cell ◽  
Conditioning Regimens

Abstract High-dose therapy with allogeneic hematopoietic transplantation (allo-SCT) from matched sibling donors has been shown to induce durable remissions in some patients with relapsed / refractory mantle cell lymphoma (MCL). The aim of this retrospective analysis from the LWP of the EBMT was to investigate the outcome of patients with MCL treated with an unrelated donor allo-SCT (MUD-allo). From January 1994 to July 2005, 66 patients with MCL, 51 males and 15 females, with a median age of 50 years (range, 22 to 68) underwent a MUD-allo and were reported to the EBMT registry. The median time from diagnosis to MUD-allo was 34 months (range, 6–131). Thirty-five patients (53%) had previously failed an autologous procedure (ASCT). Forty-five patients (68%) had sensitive disease (including 22 patients in complete remission) at transplantation, whereas 21 patients (32%) were allografted with refractory disease. Reduced intensity conditioning regimens (RIC) were used in 44 patients (67%). Patients treated with RIC were older, more heavily pre-treated and had more frequently failed an ASCT (46% vs 30%, p = 0.01) than patients treated with a conventional conditioning protocol. Total body irradiation (TBI) was used in 68% of the patients receiving conventional protocols and low-dose TBI in 23% of the RIC patients. Grade II–IV acute graft versus host disease (GVHD) developed in 35% of the cases. The cumulative incidence (CI) of non-relapse mortality (NRM) was of 21% at 6 mo and 27% at 12 mo. The CI of relapse was 35% at 1 year and 45% at 2 years. After a median follow up of 15 months (1–73), 25 patients are alive without progression, with an estimated PFS and OS at 2 years of 28% and 42%, respectively. RIC protocols were not associated with a lower NRM or a better survival. Refractory disease at MUD-allo was an adverse prognostic factor for PFS (RR 1.7; p = 0.006). Patients allografted in sensitive disease presented a better 2-year PFS and OS (34% and 48%, respectively). In conclusion, although follow up is still short, MUD-allo is a feasible procedure in poor prognosis MCL patients, with almost one third of them being alive and progression-free in this series. RIC protocols do not seem to offer any advantage in terms of long-term outcome in relation to conventional conditioning regimens.

Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: The Experience of the French SFGM-TC Group

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2392-2392
Author(s):  
Cyrille Touzeau ◽  
Richard Delarue ◽  
Christophe Leux ◽  
Murielle Roussel ◽  
Krimo Bouabdallah ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Stem Cell Transplantation ◽  
Mantle Cell Lymphoma ◽  
Retrospective Analysis ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Cell Lymphoma ◽  
Mantle Cell ◽  
Hodgkin's Lymphomas

Abstract Abstract 2392 Mantle cell lymphoma (MCL) is an aggressive and rare B-cell lymphoma entity representing around 5–8% of non-Hodgkin's lymphomas (NHLs) in adults. The hallmark of MCL is the t(11;14) which promotes cycline D1 overexpression. In France as in several European countries, autologous stem cell transplantation (ASCT) is the standard care for young MCL patients. Some recent prospective trials have suggested that ASCT could be a curable treatment for a subgroup of MCL patients. However, additional studies with long term follow-up (FU) are needed in order to confirm or not this statement. The present study is a retrospective analysis conducted on behalf of the Société Française de Greffe de Moëlle et de Thérapie Cellulaire (SFGM-TC). We aimed to investigate the outcome of MCL patients who underwent ASCT and parameters that influence both OS and EFS. All transplanted MCL patients recorded in the SFGM-TC database were eligible for the present study. Participating centers were asked to confirm the MCL diagnosis, to update biological and clinical parameters and FU. Five hundred files have been analyzed to date. The number of ASCT for MCL patients increased during the last years with 144 patients transplanted from 2003 to 2005 as compared to only 149 patients prior 2003. Since 2003, around 50 MCL patients per year undergo ASCT in France. Patients'characteristics: sex gender was male in 79.2%. At time of diagnosis, 134 patients (26.8%) were <50 years old and 128 (25.6%) were > 59 years old. More than half of the patients had a stage IV disease. The majority of these patients underwent ASCT upfront (78.8%; n=394). The conditioning regimens were BEAM (32%), TBI/Aracytin/Melphalan (TAM) (10.6%), TBI/melphalan (10.2%) or TBI/cyclophosphamide (13.2%) (data missing=156). The use of TBI for transplant conditioning decreased from 56% before 2003 to 39% after. Regarding patient outcomes, the medium FU for living patients is 34.4 months. The median EFS rate calculated after ASCT is 49.7 months and 191 experienced relapse or progression. The 3- and 5- year EFS estimates are 63.3% and 44.8%, respectively. One hundred thirty patients died and the median OS is 99 months. The 3- and 5- year OS estimates are 79.5% and 68.2%, respectively. Both EFS and OS curves show no plateau and late relapses have been reported more than 7 years after ASCT. Among patients with at least one year of FU (n=380), a secondary malignancies is reported in 27 cases (7%). In the group of patients who underwent ASCT upfront, the median EFS and OS duration are 58.8 and 114 months, respectively. For these patients (n=394), a blastic variant (p=3.10-5; p=.01), a Ki67 staining >30 (p=.01; p=.01), ECOG PS >2 (p=5.10-5; p=.01) and a high-risk MIPI (p=.003; p=.003) are adverse parameters that impact both EFS and OS, respectively. High-risk age-adjusted IPI have also an adverse prognostic impact on EFS (p=.001). At relapse, 25 patients underwent allogeneic stem cell transplantation and 19 (76%) obtained at least a partial response. This large retrospective analysis is ongoing and still represents one of the most important series of transplant MCL patients. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document